Shots:

• The approval is based on collective study results assessing Duobrii in patients with moderate to severe plaque psoriasis
• The studies resulted in superior results in comparison with vehicle- @4/2 wks. (36%- 45% vs 7%- 13%)
•  Duobrii (halobetasol propionate and tazarotene) Lotion- 0.01%/0.045%  is a prescription drug used on the skin to treat adults with plaque psoriasis and will be available in June 2019

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter